Next Article in Journal
Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to Sensitize NRAS Mutant-Melanoma to Vemurafenib
Next Article in Special Issue
Molecular Mechanisms of Vitexin: An Update on Its Anti-Cancer Functions
Previous Article in Journal
Contributions of Dietary Patterns and Factors to Regulation of Rheumatoid Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 6
10.3390/ijms26062676
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights

by
Yamile Abuchard Anaya
1,2,3,4,
Ricardo Pequeno Bracho
1,3,4,
Subhash C. Chauhan
3,4,
Manish K. Tripathi
3,4 and
Debasish Bandyopadhyay
1,5,*
1
School of Integrative Biological and Chemical Sciences, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA
2
Department of Health and Human Performance, College of Health Professions, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA
3
South Texas Center of Excellence in Cancer Research, McAllen, TX 78504, USA
4
Division of Cancer Immunology and Microbiology, Medicine, and Oncology ISU, School of Medicine, The University of Texas Rio Grande Valley, 5300 N L St., McAllen, TX 78504, USA
5
School of Earth Environment & Marine Sciences, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(6), 2676; https://doi.org/10.3390/ijms26062676
Submission received: 31 December 2024 / Revised: 9 March 2025 / Accepted: 11 March 2025 / Published: 16 March 2025
(This article belongs to the Special Issue Anti-Cancer Drugs: Natural Products, Synthetic Compounds and Potential Pharmacological Effects and Applications)
Browse Figures
Versions Notes

Abstract

B-RAF is a serine/threonine kinase that plays a crucial role in the MAPK signaling pathway, regulating cell proliferation and survival. Mutations in B-RAF, particularly V600E, are associated with several malignancies, including melanoma, colorectal cancer, and non-small cell lung cancer, making it a key therapeutic target. The development of B-RAF inhibitors, such as Vemurafenib, Dabrafenib, and second-generation inhibitors like Encorafenib, has led to significant advancements in targeted cancer therapy. However, acquired resistance, driven by MAPK pathway reactivation, RAF dimerization, and alternative signaling pathways, remains a major challenge. This review explores the molecular mechanisms of B-RAF inhibitors, their therapeutic efficacy, and resistance mechanisms, emphasizing the importance of combination strategies to enhance treatment outcomes. The current standard of care involves B-RAF and MEK inhibitors, with additional therapies such as EGFR inhibitors and immune checkpoint blockades showing potential in overcoming resistance. Emerging pan-RAF and brain-penetrant inhibitors offer new opportunities for treating refractory cancers, while precision medicine approaches, including genomic profiling and liquid biopsies, are shaping the future of B-RAF-targeted therapy.
Keywords: B-RAF; MAPK pathway; B-RAF V600E mutation; RAF kinase inhibitors; small molecule inhibitors; Vemurafenib; Dabrafenib; Encorafenib; cancer therapy; MEK inhibitors; combination therapy; drug resistance; colorectal cancer; melanoma; thyroid carcinoma; non-small cell lung carcinoma; oncology; clinical trials B-RAF; MAPK pathway; B-RAF V600E mutation; RAF kinase inhibitors; small molecule inhibitors; Vemurafenib; Dabrafenib; Encorafenib; cancer therapy; MEK inhibitors; combination therapy; drug resistance; colorectal cancer; melanoma; thyroid carcinoma; non-small cell lung carcinoma; oncology; clinical trials

Share and Cite

MDPI and ACS Style

Anaya, Y.A.; Bracho, R.P.; Chauhan, S.C.; Tripathi, M.K.; Bandyopadhyay, D. Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights. Int. J. Mol. Sci. 2025, 26, 2676. https://doi.org/10.3390/ijms26062676

AMA Style

Anaya YA, Bracho RP, Chauhan SC, Tripathi MK, Bandyopadhyay D. Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights. International Journal of Molecular Sciences. 2025; 26(6):2676. https://doi.org/10.3390/ijms26062676

Chicago/Turabian Style

Anaya, Yamile Abuchard, Ricardo Pequeno Bracho, Subhash C. Chauhan, Manish K. Tripathi, and Debasish Bandyopadhyay. 2025. "Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights" International Journal of Molecular Sciences 26, no. 6: 2676. https://doi.org/10.3390/ijms26062676

APA Style

Anaya, Y. A., Bracho, R. P., Chauhan, S. C., Tripathi, M. K., & Bandyopadhyay, D. (2025). Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights. International Journal of Molecular Sciences, 26(6), 2676. https://doi.org/10.3390/ijms26062676

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop